Last 12 months
Inside the activity.
2 purchase rows · 107 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 11 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 2 | 3 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 5 |
| Jun 2026 | 0 | 12 |
| Jul 2026 | 0 | 26 |
| Aug 2026 | 0 | 18 |
| Sep 2026 | 0 | 15 |
| Oct 2026 | 0 | 9 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 23, 2017 Filed Feb 28, 2017 00:04 UTC |
ENRIGHT PATRICK GDirector
|
SaleCommon Stock | 1,470,525 | $8.65 | $12,720,041.25 |
DisclosureSEC source: 0001209191-17-014958 · doc4.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 9,270,195 F1 · ownership.nature: Reflects shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA"). Mr. Enright is a managing member of Longitude Capital Partners, LLC, the sole general partner of LVP and LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP and LCA, except to the extent of his pecuniary interest therein. Read SEC document |
| February 22, 2017 Filed Mar 8, 2017 02:39 UTC |
WILSON JAMES NDirector
|
GiftCommon Stock | 49,893 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006773 · doc4.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,409,503 Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 23:04 UTC |
BELANOFF JOSEPH KDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 550,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000899243-17-004044 · doc4.xml · derivative · entry 1 BELANOFF JOSEPH K · CIK 0001286199 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 550,000 Underlying: Common Stock · 550,000 shares Expires 2027-02-10 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 10, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 10, 2021. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 23:00 UTC |
FISHMAN ROBERT SChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000899243-17-004040 · doc4.xml · derivative · entry 1 FISHMAN ROBERT S · CIK 0001232237 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-02-10 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 10, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 10, 2021. Read SEC document |
| February 10, 2017 Filed Feb 14, 2017 23:01 UTC |
Robb Gary CharlesChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000899243-17-004041 · doc4.xml · derivative · entry 1 Robb Gary Charles · CIK 0001529655 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2027-02-10 F1 · derivative.exercise_date: Shares subject to this stock option vest and become exercisable at the rate of 1/48th of the total number of shares on each monthly anniversary of February 10, 2017, so that the total number of shares subject to this option becomes fully vested and exercisable on February 10, 2021. Read SEC document |
| January 01, 2017 Filed Feb 14, 2018 00:33 UTC |
BAKER G LEONARD JRDirector
|
GiftCommon Stock | 0 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-18-002815 · doc5.xml · nonDerivative · entry 1 BAKER G LEONARD JR · CIK 0001201715 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Ltd Partnership Disclosed balance after: 2,613,634 F1 · kind: Represents gift of limited partnership interests in a limited partnership to other limited partners. The reporting person disclaims beneficial ownership of the shares held by the limited partnership except as to the reporting person's pecuniary interest therein. F2 · ownership.nature: Shares held by a limited partnership of which the reporting person is a trustee of a trust which is the general partner. The reporting person disclaims beneficial ownership in these shares except as to the reporting person's pecuniary interest therein. Read SEC document |
| December 29, 2016 Filed Feb 14, 2017 22:52 UTC |
MAHONEY DAVID LDirector
|
GiftCommon Stock | 33,647 | $7.29 | $245,286.63 |
DisclosureSEC source: 0000899243-17-004022 · doc5.xml · nonDerivative · entry 1 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,135,673 Read SEC document |
| December 15, 2016 Filed Dec 19, 2016 18:29 UTC |
Tammenoms Bakker Juliet10% owner
|
GiftCommon Stock | 70,671 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-155808 · doc4.xml · nonDerivative · entry 1 Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,539 Read SEC document |
| December 12, 2016 Filed Dec 15, 2016 01:28 UTC |
Tammenoms Bakker Juliet10% owner
|
OtherCommon Stock | 204,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-155279 · doc4.xml · nonDerivative · entry 1 Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,210 F1 · kind: On November 28, 2016, Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") completed a pro rata distribution of shares of common stock of the Issuer to its partners for no consideration. Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP and LCA, received a pro rata allocation of the distributed shares in accordance with its ownership, and on December 12, 2016, further distributed its allocation to its managing members. Juliet Tammenoms Bakker, as a managing member of Longitude Capital, acquired the shares noted in this Form through such distribution. Read SEC document |
| December 12, 2016 Filed Dec 15, 2016 01:26 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
OtherCommon Stock | 204,210 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-155276 · doc4.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,210 F1 · kind: On November 28, 2016, Longitude Venture Partners, L.P. ("LVP") and Longitude Capital Partners, L.P. ("LCA") completed a pro rata distribution of shares of common stock of the Issuer to its partners for no consideration. Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP and LCA, received a pro rata allocation of the distributed shares in accordance with its ownership, and on December 12, 2016, further distributed its allocation to its managing members. Patrick G. Enright, as a managing member of Longitude Capital, acquired the shares noted in this Form through such distribution. Read SEC document |
| November 28, 2016 Filed Dec 1, 2016 02:47 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
OtherCommon Stock | 58,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152566 · doc4.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 121,153 F3 · kind: Represents a pro rata distribution of shares of common stock of the Issuer held of record by LCA to its partners for no consideration. LCP, which is the sole general partner of LCA, received a pro rata allocation of the distributed shares in accordance with its ownership. F4 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by LCA. Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein. Read SEC document |
| November 28, 2016 Filed Dec 1, 2016 02:47 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
OtherCommon Stock | 2,941,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152566 · doc4.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 10,834,849 F1 · kind: Represents a pro rata distribution of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP") to its partners for no consideration. Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, received a pro rata allocation of the distributed shares in accordance with its ownership. F2 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. Patrick G. Enright is a managing member of Longitude Capital. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein Read SEC document |
| November 28, 2016 Filed Dec 1, 2016 02:52 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
OtherCommon Stock | 58,950 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152569 · doc4.xml · nonDerivative · entry 2 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 121,153 F3 · kind: Represents a pro rata distribution from LCA to its partners for no consideration. LCP, which is the sole general partner of LCA, received a pro rata allocation of the distributed shares in accordance with its ownership. F4 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by LCA. This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 28, 2016 Filed Dec 1, 2016 02:52 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
OtherCommon Stock | 2,941,050 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-152569 · doc4.xml · nonDerivative · entry 1 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,834,849 F1 · kind: Represents a pro rata distribution from Longitude Venture Partners, L.P. ("LVP") to its partners for no consideration. Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, received a pro rata allocation of the distributed shares in accordance with its ownership. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by LVP. This report is filed jointly by LVP, Longitude Capital, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 25, 2016 Filed Nov 26, 2016 02:08 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 290 | $9.39 | $2,722.20 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 6 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,103 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.4600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 25, 2016 Filed Nov 26, 2016 02:08 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 14,451 | $9.39 | $135,650.09 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 5 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,775,899 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.4600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 25, 2016 Filed Nov 26, 2016 02:05 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 290 | $9.39 | $2,722.20 |
DisclosureSEC source: 0001209191-16-152055 · doc4.xml · nonDerivative · entry 6 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,103 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.4600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein. Read SEC document |
| November 25, 2016 Filed Nov 26, 2016 02:05 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 14,451 | $9.39 | $135,650.09 |
DisclosureSEC source: 0001209191-16-152055 · doc4.xml · nonDerivative · entry 5 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 13,775,899 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.4600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein. Read SEC document |
| November 23, 2016 Filed Nov 26, 2016 02:08 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 248 | $9.30 | $2,307.34 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 4 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,393 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.3400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 23, 2016 Filed Nov 26, 2016 02:08 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 12,352 | $9.30 | $114,920.54 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 3 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,790,350 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.3400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 23, 2016 Filed Nov 26, 2016 02:05 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 248 | $9.30 | $2,307.34 |
DisclosureSEC source: 0001209191-16-152055 · doc4.xml · nonDerivative · entry 4 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,393 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.300 to $9.3400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein. Read SEC document |
| November 23, 2016 Filed Nov 26, 2016 02:05 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 12,352 | $9.30 | $114,920.54 |
DisclosureSEC source: 0001209191-16-152055 · doc4.xml · nonDerivative · entry 3 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 13,790,350 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.300 to $9.3400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein. Read SEC document |
| November 22, 2016 Filed Nov 26, 2016 02:08 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 189 | $9.33 | $1,763.31 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 2 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,641 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.300 to $9.3600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 22, 2016 Filed Nov 26, 2016 02:08 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 9,411 | $9.33 | $87,801.81 |
DisclosureSEC source: 0001209191-16-152057 · doc4.xml · nonDerivative · entry 1 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,802,702 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.300 to $9.3600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 22, 2016 Filed Nov 26, 2016 02:05 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 189 | $9.33 | $1,763.31 |
DisclosureSEC source: 0001209191-16-152055 · doc4.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,641 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.3600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein. Read SEC document |
| November 22, 2016 Filed Nov 26, 2016 02:05 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 9,411 | $9.33 | $87,801.81 |
DisclosureSEC source: 0001209191-16-152055 · doc4.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 13,802,702 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3000 to $9.3600. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 02:10 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 2,327 | $9.39 | $21,841.22 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 6 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,830 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3300 to $9.4800. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 02:10 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 116,058 | $9.39 | $1,089,320.39 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 5 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,812,113 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3300 to $9.4800. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 02:02 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 2,327 | $9.39 | $21,841.22 |
DisclosureSEC source: 0001209191-16-151522 · doc4.xml · nonDerivative · entry 6 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 180,830 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3300 to $9.4800. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein. Read SEC document |
| November 21, 2016 Filed Nov 22, 2016 02:02 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 116,058 | $9.39 | $1,089,320.39 |
DisclosureSEC source: 0001209191-16-151522 · doc4.xml · nonDerivative · entry 5 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 13,812,113 F5 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.3300 to $9.4800. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 02:10 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 1,976 | $9.47 | $18,719.83 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 4 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 183,157 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.4500 to $9.5400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 02:10 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 98,586 | $9.47 | $933,964.33 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 3 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,928,171 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.4500 to $9.5400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 02:02 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 1,976 | $9.47 | $18,719.83 |
DisclosureSEC source: 0001209191-16-151522 · doc4.xml · nonDerivative · entry 4 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 183,157 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.4500 to $9.5400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein. Read SEC document |
| November 18, 2016 Filed Nov 22, 2016 02:02 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 98,586 | $9.47 | $933,964.33 |
DisclosureSEC source: 0001209191-16-151522 · doc4.xml · nonDerivative · entry 3 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 13,928,171 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.4500 to $9.5400. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein. Read SEC document |
| November 17, 2016 Filed Nov 22, 2016 02:10 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 6,389 | $9.64 | $61,611.68 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 2 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 185,133 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5300 to $9.8000. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 17, 2016 Filed Nov 22, 2016 02:10 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
Longitude Capital Associates, L.P.10% owner
|
SaleCommon Stock | 318,764 | $9.64 | $3,073,968.76 |
DisclosureSEC source: 0001209191-16-151526 · doc4.xml · nonDerivative · entry 1 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,026,757 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5300 to $9.8000. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 17, 2016 Filed Nov 22, 2016 02:02 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 6,389 | $9.64 | $61,611.68 |
DisclosureSEC source: 0001209191-16-151522 · doc4.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 185,133 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5300 to $9.8000. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein. Read SEC document |
| November 17, 2016 Filed Nov 22, 2016 02:02 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 318,764 | $9.64 | $3,073,968.76 |
DisclosureSEC source: 0001209191-16-151522 · doc4.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 14,026,757 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5300 to $9.8000. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.. F2 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 00:32 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Associates, L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
|
SaleCommon Stock | 342 | $9.51 | $3,251.98 |
DisclosureSEC source: 0001209191-16-151019 · doc4.xml · nonDerivative · entry 4 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 191,522 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.5450. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 00:32 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Associates, L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
|
SaleCommon Stock | 17,052 | $9.51 | $162,142.35 |
DisclosureSEC source: 0001209191-16-151019 · doc4.xml · nonDerivative · entry 3 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,345,521 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.5450. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 21:36 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 342 | $9.51 | $3,251.98 |
DisclosureSEC source: 0001209191-16-150891 · doc4.xml · nonDerivative · entry 4 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 191,522 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.5450. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Nov 17, 2016 21:36 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 17,052 | $9.51 | $162,142.35 |
DisclosureSEC source: 0001209191-16-150891 · doc4.xml · nonDerivative · entry 3 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 14,345,521 F4 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.5450. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein. Read SEC document |
| November 16, 2016 Filed Feb 14, 2017 22:59 UTC |
WILSON JAMES NDirector
|
GiftCommon Stock | 112,000 | $9.46 | $1,059,520.00 |
DisclosureSEC source: 0000899243-17-004037 · doc5.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 789,067 Read SEC document |
| November 16, 2016 Filed Mar 2, 2017 23:19 UTC Amendment |
WILSON JAMES NDirector
|
GiftCommon Stock | 112,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006141 · doc5a.xml · nonDerivative · entry 1 WILSON JAMES N · CIK 0001236387 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · James N. Wilson and Pamela D. Wilson Trust Disclosed balance after: 1,459,396 Read SEC document |
| November 15, 2016 Filed Nov 18, 2016 00:32 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Associates, L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
|
SaleCommon Stock | 3,094 | $9.55 | $29,558.22 |
DisclosureSEC source: 0001209191-16-151019 · doc4.xml · nonDerivative · entry 2 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 191,864 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.7200. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). This report is jointly filed by LCA, Longitude Capital, the sole general partner of LCA, and Ms. Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LCA. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 15, 2016 Filed Nov 18, 2016 00:32 UTC |
Longitude Venture Partners L.P.10% owner
Longitude Capital Associates, L.P.10% owner
Longitude Capital Partners, LLC10% owner
Tammenoms Bakker Juliet10% owner
|
SaleCommon Stock | 154,359 | $9.55 | $1,474,653.27 |
DisclosureSEC source: 0001209191-16-151019 · doc4.xml · nonDerivative · entry 1 Longitude Venture Partners L.P. · CIK 0001419701 · 10% owner Longitude Capital Associates, L.P. · CIK 0001430719 · 10% owner Longitude Capital Partners, LLC · CIK 0001430720 · 10% owner Tammenoms Bakker Juliet · CIK 0001431159 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,362,573 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.7200. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected. F2 · ownership.direct: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). This report is filed jointly by LVP, Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP, and Juliet Tammenoms Bakker, a managing member of Longitude Capital, with respect to the securities held and transactions effected by LVP. LVP may also be deemed a director by virtue of its right to nominate a representative to serve on the Issuer's Board of Directors. Patrick G. Enright currently serves as LVP's representative on the Issuer's Board of Directors and files separate reports under Section 16(a) of the Securities Exchange Act of 1934 to report transactions in securities of the Issuer. Each of Longitude Capital and Ms. Bakker disclaims beneficial ownership of these securities, except to the extent of their respective pecuniary interest therein. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:36 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 3,094 | $9.55 | $29,558.22 |
DisclosureSEC source: 0001209191-16-150891 · doc4.xml · nonDerivative · entry 2 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LCA Disclosed balance after: 191,864 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.7200. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.. F3 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Capital Associates, L.P. ("LCA"). Patrick G. Enright is a managing member of Longitude Capital, the sole general partner of LCA. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LCA, except to the extent of his pecuniary interest therein. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:36 UTC |
ENRIGHT PATRICK GDirector · 10% owner
|
SaleCommon Stock | 154,359 | $9.55 | $1,474,653.27 |
DisclosureSEC source: 0001209191-16-150891 · doc4.xml · nonDerivative · entry 1 ENRIGHT PATRICK G · CIK 0001253886 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By LVP Disclosed balance after: 14,362,573 F1 · price: Reflects sales of common stock executed in multiple transactions at prices ranging from $9.5000 to $9.7200. The price reported reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, Corcept Therapeutics Incorporated or a security holder of Corcept Therapeutics Incorporated full information regarding the number of shares and prices at which the sales were effected.. F2 · ownership.nature: Reflects transactions and holdings of shares of common stock of the Issuer held of record by Longitude Venture Partners, L.P. ("LVP"). Patrick G. Enright is a managing member of Longitude Capital Partners, LLC ("Longitude Capital"), the sole general partner of LVP. Mr. Enright serves on the Board of Directors of the Issuer as the nominee of LVP. Mr. Enright disclaims beneficial ownership of the securities of the Issuer held of record by LVP, except to the extent of his pecuniary interest therein. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 01:02 UTC |
MAHONEY DAVID LDirector
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $2.70 | $0.00 |
DisclosureSEC source: 0000899243-16-033409 · doc4.xml · derivative · entry 3 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires 2017-12-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Fully exercisable. Read SEC document |
| November 11, 2016 Filed Nov 15, 2016 01:02 UTC |
MAHONEY DAVID LDirector
|
SaleCommon Stock | 30,000 | $9.35 | $280,500.00 |
DisclosureSEC source: 0000899243-16-033409 · doc4.xml · nonDerivative · entry 2 MAHONEY DAVID L · CIK 0001224091 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David L. Mahoney and Winnifred C. Ellis 1998 Family Trust Disclosed balance after: 1,169,320 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.